Literature DB >> 11932598

Soft-tissue flap coverage maximizes limb salvage after allograft bone extremity reconstruction.

Dimitrios P Mastorakos1, Joseph J Disa, Edward Athanasian, Patrick Boland, John H Healey, Peter G Cordeiro.   

Abstract

Limb salvage after extremity tumor ablation may include the use of allograft bone. The primary complication of this method is infection of the allograft, which can lead to limb loss in up to 50 percent of cases. The purpose of this study is to evaluate the efficacy of primary muscle flap coverage in the setting of allograft bone limb salvage surgery. This study is a prospective review of all patients with flap coverage of extremity allografts over the 10-year period 1991 to 2001. There were 20 patients (11 male and nine female patients) with an average age of 28 years (range, 6 to 72 years). Flap coverage was primary in 16 patients and delayed in four. Delayed coverage was performed for failed wounds that did not have a primary soft-tissue flap. Pathologic findings included osteosarcoma in nine patients, Ewing sarcoma in five patients, malignant fibrohistiocytoma in two patients, chondrosarcoma in two patients, synovial sarcoma in one patient, and leiomyosarcoma in one patient. Allograft reconstruction was performed for the upper extremity in 12 patients and for the lower extremity in eight patients. Flap reconstruction was accomplished with 20 pedicle flaps in 17 patients (latissimus dorsi, 12; gastrocnemius, four; soleus, three; and fasciocutaneous flap, one) and four free flaps (rectus abdominis, three; latissimus dorsi, one) in four patients. All pedicled flaps survived. There was one flap failure in the entire series, which was a free rectus abdominis flap. This case resulted in the only limb loss noted. The follow-up period ranged from 1 to 50 months (average, 12.35 months). At the time of final follow-up, three patients were dead of disease and 17 were alive with intact extremities. The overall limb salvage rate in the setting of bone allograft and soft-tissue flap coverage was 95 percent (19 of 20). Reoperation for bone-related complications was required in 50 percent (two of four) of cases receiving delayed flap coverage compared with 19 percent (three of 16) of patients with primary flap coverage (statistically not significant). The results of this study support the use of soft-tissue flap coverage for allograft limb reconstruction. In this series, no limb was lost in the setting of a viable flap. Reoperation was markedly reduced in the setting of primary flap coverage. Pedicled or microvascular transfer of well-vascularized muscle can be used to wrap the allograft and minimize devastating wound complications potentially leading to loss of allograft and limb.

Entities:  

Mesh:

Year:  2002        PMID: 11932598     DOI: 10.1097/00006534-200204150-00012

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  4 in total

1.  Pedicled Latissimus Dorsi Flap for Shoulder Soft-Tissue Reconstruction After Excision of a Musculoskeletal Neoplasm.

Authors:  Ryan Engdahl; Joseph Disa; Edward A Athanasian; John H Healey; Peter G Cordeiro; Nicola Fabbri
Journal:  JBJS Essent Surg Tech       Date:  2016-04-27

2.  Analysis of surgical site infection after musculoskeletal tumor surgery: risk assessment using a new scoring system.

Authors:  Satoshi Nagano; Masahiro Yokouchi; Takao Setoguchi; Hiromi Sasaki; Hirofumi Shimada; Ichiro Kawamura; Yasuhiro Ishidou; Junichi Kamizono; Takuya Yamamoto; Hideki Kawamura; Setsuro Komiya
Journal:  Sarcoma       Date:  2014-01-08

3.  Radiation-Induced Wound Infections in Operated Soft Tissue Sarcomas: An Unbelievable Challenge in a Series of Five Cases.

Authors:  Yash Wagh; Aditya Menon; Bimal Mody; Vikas M Agashe; Manish Agarwal
Journal:  J Orthop Case Rep       Date:  2019

4.  Effectiveness of circular hexapod external fixation with soft tissue reconstruction in treating severe knee dislocation due to burn scarring: a case report.

Authors:  Koji Nozaka; Naohisa Miyakoshi; Hidetomo Saito; Hiroaki Kijima; Motoki Mita; Yoichi Shimada
Journal:  BMC Musculoskelet Disord       Date:  2020-09-28       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.